Volume 8, Number 4—April 2002
Research
Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1
Table 3
Case | MIC/sensitivity status | |||||
---|---|---|---|---|---|---|
ciprofloxacin | levofloxacin | ofloxacin | norfloxacin | gentamicin | furodantin | |
1 | /S | |||||
2 | <1 μg/mL | <4 μg/mL | <1 μg/mL | <32 μg/mL | ||
3 | >2 μg/mL/R | >4 μg/mL/R | >8 μg/mL | <1 μg/mL | <32 μg/mL | |
4 | >2 μg/mL/R | >8 μg/mL | <1 μg/mL | <32 μg/mL | ||
5 | <1 μg/mL/S | 4 μg/mL/I | <1 μg/mL/S | |||
6 | >2 μg/mL/R | >4 μg/mL/R | 8 μg/mL/I | |||
7 | >2 μg/mL/R | >4 μg/mL/R | >8 μg/mL/R | |||
8 | >2 μg/mL/R | >4 μg/mL/R | >8 μg/mL/R | |||
9 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL | ||
10 | =2 μg/mL/I | <2 μg/mL/S | <1 μg/mL/S | =64 μg/mL | ||
11 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL | ||
12 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL/S | ||
13 | >2 μg/mL/R | >4 μg/mL/R | <1 μg/mL/S | <32 μg/mL/S | ||
14 | <1 μg/mL/S | <2 μg/mL/S | <1 μg/mL/S | <32 μg/mL | ||
15 | /R | |||||
16 | ||||||
17 | ||||||
18 | <1 μg/mL | <1 μg/mL | ||||
19 | <0.5 μg/mL/S | <1 μg/mL/S | <2 μg/mL/S | |||
Total | 9/16=R | 4/5=R | 4/7=R | 3/16=R |
aFFY=Federal fiscal year; S=susceptible, I=intermediate and R=resistant based on laboratory interpretative criteria.
1A portion of this material was presented at the 11th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America in Toronto, Ontario, Canada (Abstract #49), April 2001.
Page created: July 15, 2010
Page updated: July 15, 2010
Page reviewed: July 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.